https://www.selleckchem.com/pr....oducts/sodium-oxamat
lly designed to weigh against the significant risks of irAEs. This phase I study assessed the safety, pharmacokinetics, and efficacy of MIW815 (ADU-S10, a novel synthetic cyclic dinucleotide that activates the stimulator of interferon genes (STING) pathway, in patients with advanced/metastatic cancers. Patients ( = 47) received weekly intratumoral injections of MIW815, 50-6400 μg, 3-weeks-on/1-week-off. A maximum tolerated dose was not reached. Most common treatment-related adverse events were pyrexia (17%), chills, and injecti
Like
Comment
Share
